← Leaderboards
Kenneth A Foon
University Of Cincinnati
$1,472,072
Attributed
$1,472,072
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $244.7K · FY2005–08$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,472,072 · 4
By mechanism
P30$743,802 · 1
R01$613,160 · 1
U10$81,981 · 1
R03$33,129 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Cincinnati
Same institution · by research overlap
- Karen E Knudsen$24,017,647
- Malaya B Chatterjee$3,816,092
- Natalie Kreitzer$855,878
- Erik Knudsen$18,973,850
- Joseph Paul Broderick$95,619,410
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectMelanomaClinical TrialsHuman Therapy EvaluationNeoplasm /Cancer ImmunotherapyLymphomaCellular ImmunityNeoplasm /Cancer VaccineGangliosidesAntiidiotype AntibodyDrug Screening /EvaluationHumoral ImmunityCancer PreventionCancer Information SystemBleomycinCancer Immunology ScienceCancer Immunology FunctionBiotechnologyAntineoplasticsBreast NeoplasmsClinical Trial Phase IiBiologicalClinical Trial Phase I
Grant awards (10)
CORE--PROTOCOL SPECIFIC RESEARCH$227,046
P30 · FY2008 · CA · contact PI
CORE--PROTOCOL SPECIFIC RESEARCH$244,689
P30 · FY2007 · CA · contact PI
CORE--PROTOCOL SPECIFIC RESEARCH$93,382
P30 · FY2006 · CA · contact PI
CORE--PROTOCOL SPECIFIC RESEARCH$90,663
P30 · FY2005 · CA
Ganglioside GD2 as Target for Immunotherapy in Melanoma$281,913
R01 · FY2004 · CA
CORE--PROTOCOL SPECIFIC RESEARCH$88,022
P30 · FY2004 · CA
Ganglioside GD2 as Target for Immunotherapy in Melanoma$331,247
R01 · FY2003 · CA
SOUTHWEST ONCOLOGY GROUP$41,401
U10 · FY2001 · CA
SOUTHWEST ONCOLOGY GROUP$40,580
U10 · FY2000 · CA
ANTIIDIOTYPE VACCINE WITH IL2 FOR ADVANCED MELANOMA$33,129
R03 · FY2000 · CA